Clinical and instrumental characteristics of psoriatic arthritis in men and women. Data from a cohort observational study

Cover Page

Cite item

Full Text

Abstract

Aim. To study and compare the clinical and imaging characteristics of psoriatic arthritis (PsA) in men and women.

Materials and methods. The study included 956 PsA patients observed in the Russian register, 411 (43%) men and 545 (57%) women. The average age of men/women was 46.0±16.50/50.7±17.20 years (p<0.001), the duration of PsA was 9.9±6.4/10.3±7.6 years (p>0.05), the age at the time of PsA establishment was 37.1±12.30/41.8±13.5 years (p<0.001). Rheumatological examination, X-ray of the pelvis, hands, feet were performed, the LEI, plantar fascia tenderness, body surface area (BSA), body mass index (BMI), CRP, HLA-B27 were determined. Patients filled out assessment scales of pain (Pain), disease activity (patient global assessment of disease activity – PGA), questionnaires HAQ-DI. The indices of Disease Activity in PSoriatic Arthritis (DAPSA), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), criteria of minimal disease activity (MDA) were evaluated.

Results. The following differences in the course of PsA in men/women were revealed: X-ray sacroiliitis was detected in 175 (42.6%)/153 (28.1%); p<0.001; the presence of erosions of the joints of the hands and feet – 138 (33.6%)/170 (31.2%); p=0.435; LEI≥3 – 34 (11.4%)/78 (20.9%); p=0.001; Pain – at 48.5±22.60/51.5±22.80 mm VAS; p=0.043; PGA – 50.2±23.07/54.0±21.91 mm VAS; p=0.010; moderate and severe functional disorders (HAQ-DI) were more often observed in women (p=0.002 and p<0.001, respectively); the average value of DAPSA is 26.4±16.8/31.9±22.58; p<0.001; average BASDAI value: 2.7±2.83/1.8±2.78; p<0.001; MDA was achieved in 13 (3.2%)/22 (4.1%); p=0.486; BSA>10% – 54 (13.1%)/102 (18.7%); p=0.021; comorbid diseases – 154 (37%)/277 (51%); p<0.001. At the time of inclusion in the register, the proportion of patients receiving biologic disease-modifying anti-rheumatic drugs was higher in the group of men.

Conclusion. Our data, based on a large cohort study, demonstrate that PsA debuts in women at a later age than in men, the course of the disease is characterized by higher activity of peripheral arthritis, more pronounced functional disorders and a high prevalence of comorbid diseases. This creates a heavier burden of PsA in women and indicates that gender is an important characteristic of the patient that should be used to predict the course, therapeutic response and progression of the disease.

About the authors

Yulia L. Korsakova

Nasonova Research Institute of Rheumatology

Author for correspondence.
Email: yulkorsakova@bk.ru
ORCID iD: 0000-0001-5968-2403

кандидат мед. наук, ст. науч. сотр. лаб. псориатического артрита

Russian Federation, Moscow

Tatiana V. Korotaeva

Nasonova Research Institute of Rheumatology

Email: yulkorsakova@bk.ru
ORCID iD: 0000-0003-0579-1131

доктор мед. наук, нач. отд. спондилоартритов

Russian Federation, Moscow

Elena Iu. Loginova

Nasonova Research Institute of Rheumatology

Email: yulkorsakova@bk.ru
ORCID iD: 0000-0001-6875-4552

кандидат мед. наук, ст. науч. сотр. лаб. псориатического артрита

Russian Federation, Moscow

Elena E. Gubar

Nasonova Research Institute of Rheumatology

Email: yulkorsakova@bk.ru
ORCID iD: 0000-0001-5015-7143

кандидат мед. наук, науч. сотр. лаб. псориатического артрита

Russian Federation, Moscow

Andriy V. Petrov

Vernadsky Crimean Federal University; Semashko Clinical Hospital; Ministry of Health of the Republic of Crimea

Email: yulkorsakova@bk.ru
ORCID iD: 0000-0002-6398-2545

доктор мед. наук, проф. Медицинской академии ФГАОУ ВО «КФУ им. В.И. Вернадского», гл. внештат. специалист-ревматолог Минздрава Республики Крым

Russian Federation, Simferopol; Simferopol; Simferopol

Irina M. Patrikeeva

Tyumen Regional Clinical Hospitai No. 1; Tyumen Regional Healthcare Department

Email: yulkorsakova@bk.ru
ORCID iD: 0000-0003-0530-0080

зав. ревматологическим отд-нием ГБУЗ ТО ОКБ №1, гл. специалист-ревматолог Департамента здравоохранения Тюменской области

Russian Federation, Tyumen; Tyumen

Irina F. Umnova

Regional Clinical Hospital

Email: yulkorsakova@bk.ru
ORCID iD: 0000-0002-2168-8954

врач-ревматолог

Russian Federation, Omsk

Valentina N. Sorotskaya

Tula State University

Email: yulkorsakova@bk.ru
ORCID iD: 0000-0003-3684-7310

доктор мед. наук, доц., проф. каф. внутренних болезней Медицинского института

Russian Federation, Tula

Igor N. Pristavskii

Clinical Rheumatology Hospital No. 25

Email: yulkorsakova@bk.ru
ORCID iD: 0000-0002-2189-3085

врач-ревматолог

Russian Federation, Saint Petersburg

Mariia V. Sedunova

Clinical Rheumatology Hospital No. 25

Email: yulkorsakova@bk.ru
ORCID iD: 0000-0002-3355-2093

врач-ревматолог

Russian Federation, Saint Petersburg

Evgeny L. Nasonov

Nasonova Research Institute of Rheumatology; Sechenov First Moscow State Medical University (Sechenov University)

Email: yulkorsakova@bk.ru
ORCID iD: 0000-0002-1598-8360

акад. РАН, доктор мед. наук, проф., науч. рук. ФГБНУ «НИИ ревматологии им. В.А. Насоновой», проф. каф. внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)

Russian Federation, Moscow; Moscow

References

  1. Ревматология. Российские клинические рекомендации. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2020 [Revmatologiia. Rossiiskie klinicheskie rekomendatsii. Pod red. EL Nasonova. Moscow: GEOTAR-Media, 2020 (in Russian)].
  2. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957-70. doi: 10.1056/NEJMra1505557
  3. Bragazzi NL, Bridgewood C, Watad A, et al. Sex-based medicine meets psoriatic arthritis: Lessons learned and to learn. Front Immunol. 2022;13:849560. doi: 10.3389/fimmu.2022.849560
  4. Tarannum S, Leung YY, Johnson SR, et al. Sex- and gender-related differences in psoriatic arthritis. Nat Rev Rheumatol. 2022;18(9):513-26. doi: 10.1038/s41584-022-00810-7
  5. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665-73. doi: 10.1002/art.21972
  6. Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrumentspecific to psoriatic arthritis. Arthritis Rheum. 2008;59(5):686-91. doi: 10.1002/art.23568
  7. Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): Defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75(5):811-8. doi: 10.1136/annrheumdis-2015-207507
  8. Aletaha D, Alasti F, Smolen JS. Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression. Ann Rheum Dis. 2017;76(2):418-21. doi: 10.1136/annrheumdis-2016-209511
  9. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286-91. PMID: 7699630
  10. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: A proposed objective target for treatment. Ann Rheum Dis. 2010;69(1):48-53. doi: 10.1136/ard.2008.102053
  11. Braaten TJ, Zhang C, Presson AP, et al. Gender differences in psoriatic arthritis with fatigue, pain, function, and work disability. J Psoriasis Psoriatic Arthritis. 2019;4(4):192-7. doi: 10.1177/2475530319870776
  12. Duruöz MT, Gezer HH, Nas K, et al. Gender-related differences in disease activity and clinical features in patients with peripheral psoriatic arthritis: A multi-center study. Joint Bone Spine. 2021;88(4):105177. doi: 10.1016/j.jbspin.2021.105177
  13. Passia E, Vis M, Coates LC, et al. Sex-specific differences and how to handle them in early psoriatic arthritis. Arthritis Res Ther. 2022;24(1):22. doi: 10.1186/s13075-021-02680-y
  14. Van Kuijk AWR, Nurmohamed MT, Siebert S, et al. Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: Real-world data. Rheumatology (Oxford). 2023;62(10):3382-90. doi: 10.1093/rheumatology/kead089
  15. Kojanova M, Fialova J, Cetkovska P, et al. Demographic data, comorbidities, quality of life, and survival probability of biologic therapy associated with sex-specific differences in psoriasis in the Czech Republic. Dermatol Ther. 2021;34(2):e14849. doi: 10.1111/dth.14849
  16. Gossec L, Walsh JA, Michaud K, et al. Women with psoriatic arthritis experience higher disease burden than men: findings from a real-world survey in the United States and Europe. J Rheumatol. 2023;50(2):192-6. doi: 10.3899/jrheum.220154
  17. Coates LC, van der Horst-Bruinsma IE, Lubrano E, et al. Sex-specific differences in patients with psoriatic arthritis: A systematic review. J Rheumatol. 2023;50(4):488-96. doi: 10.3899/jrheum.220386

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Comparison of the prevalence of high psoriatic arthritis activity (DAPSA>28), spondylitis (BASDAI>4), and minimal disease activity in males and females.

Download (69KB)
3. Fig. 2. Comparison of the severity of psoriasis in males and females.

Download (63KB)

Copyright (c) 2024 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies